Results demonstrate a significant survival benefit in the cTMB-H / HRP subset: median OS of almost 6 years (68 months) with Vigil vs. less than 2 ...

A new clinical study published in the International Journal of Gynecological Cancer reports encouraging results for women ...

In this systematic review and meta-analysis, researchers examined outcomes among advanced ovarian cancer patients who ...

Zoe Wilson thought she may be at risk. It wasn’t just a vague gut feeling: the risk was demonstrable and clear, running ...

Ovarian cancer reprograms the omentum to shield hidden tumors. New research suggests total omentectomy may curb recurrence and improve long-term outcomes.

Lynch Syndrome (LS) is a common hereditary condition that significantly increases the lifetime risk of developing multiple ...

"Our research demonstrates the power of GLP-1 therapies to transform health outcomes, with especially promising results for ...

More than two-thirds of deaths from ovarian cancer are attributable to high-grade serous carcinoma. In one particularly ...

Sevabertinib, targeting HER2 and EGFR mutations, received FDA breakthrough designation for HER2+ NSCLC, showing a 59% overall ...

When Jayant Parthasarathy lost family members to breast, brain, ovarian, and prostate cancers, his next mission was clear.

Hamad Medical Corporation (HMC), in partnership with Qatar Foundation (QF), the Qatar Precision Health Institute (QPHI), ...

A recent study links chemotherapy to impaired ovarian function and fertility through oxidative damage to ovarian follicles.